J. Puente
Complutense University of Madrid
11 Papers
51 Citations
J. Puente is an academic researcher from Complutense University of Madrid. The author has contributed to research in topics: Medicine & Lung cancer. The author has an hindex of 7, co-authored 11 publications. Previous affiliations of J. Puente include Hospital Clínico San Carlos.
Chat about Author
Papers
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
Tomasz M. Beer,Eugene D. Kwon,Charles G. Drake,Karim Fizazi,Christopher J. Logothetis,Gwenaelle Gravis,Vinod Ganju,Jonathan Polikoff,Fred Saad,Piotr Humanski,Josep M. Piulats,Pablo González Mella,Siobhan Ng,Dirk Jaeger,Francis Parnis,Fabio Franke,J. Puente,Roman Carvajal,Lisa Sengeløv,M. Brent McHenry,Arvind Varma,Alfonsus J. M. van den Eertwegh,Winald R. Gerritsen +22 more
TL;DR: Ipilimumab did not improve OS in patients with metastatic castration-resistant prostate cancer and the observed increases in progression-free survival and prostate-specific antigen response rates suggest antitumor activity in a patient subset.
698
Multidisciplinary expert opinion on the treatment consensus for patients with EGFR mutated NSCLC with brain metastases.
Santiago Ponce,Jordi Bruna,Oscar Juan,Rafael López,Alejandro Navarro,Ana Laura Ortega,J. Puente,Eugenia Verger,Adela Bartolomé,Ernest Nadal +9 more
TL;DR: An expert opinion consensus on the management of patients with EGFR mutated NSCLC with brain metastases is developed and contains 26 recommendations and 20 conclusion statements across 21 questions in 7 areas, as well as a first-line treatment algorithm.
14
Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function
Jon Zugazagoitia,Aránzazu Manzano,Javier Sastre,Javier Sastre,José M. Ladero,José M. Ladero,J. Puente,J. Puente,Eduardo Díaz-Rubio,Eduardo Díaz-Rubio +9 more
TL;DR: The benefit of sorafenib in Child–Pugh B patients, if exist, may be limited by frequent liver-related events, especially in decompensated patients, and then, toxicity and impact in quality of life should be carefully monitored.
14
Iatrogenic intestinal obstruction: a rare complication of capsule endoscopy in a patient with familial adenomatous polyposis.
Pedro Pérez-Segura,I. Siso,R. Luque,Helena Olivera,S. Díaz,Julio Mayol,Coralia Bueno,J. Puente,Eduardo Díaz-Rubio +8 more
TL;DR: The detection of ileal polyps in patients with FAP could have an impact on their management, how− ever, and complications, such as retention of the capsule, are exceptional.
Erlotinib versus pemetrexed for pretreated non-squamous non-small cell lung cancer patients in clinical practice.
Jon Zugazagoitia,J. Puente,Jose-Luis Gonzalez-Larriba,A. Manzano,Miguel Sotelo,Susana Hernandez,Julián Sanz,P. Pérez,Eduardo Díaz-Rubio +8 more
TL;DR: Erlotinib should be considered as another equal option in second-line treatment for EGFR wild-type patients as well as for subpopulations with unknown mutational status and smoking history could be a useful clinical marker to choose a second- line treatment.
9